Intellia Therapeutics, Inc. NTLA 深 沪
等待开盘 07-03 09:30:00 美东时间
17.61
+0.370
+2.15%
华盛通- 最 高18.48
- 今 开17.63
- 成交量 295.11万股
- 最 低 17.32
- 昨 收 17.24
- 总市值 24.61亿
- 52周最高 28.25
- 市盈率 静 --
- 换手率 2.11%
- 52周最低 7.95
- 委 比 88.79%
- 总股本 1.40亿
- 历史最高 202.73
- 量 比 0.68
- 振 幅 6.73%
- 历史最低 5.90
- 每 手 1
- 风险率 3.66%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze
Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names where bearish positioning has reached extreme territory, setting the stage for violent moves if sentiment flips. LCID stock is moving. See the chart and price action here. For short sellers, these are h...
06-29 22:35
美股牛股 | 量子计算概念重回风口！QTEX飙涨超70%，ARQQ涨近32%；GPUS大涨超75%，将转型AI数据中心业务
量子计算概念重回风口！QTEX飙涨超70%，ARQQ涨近32%；GPUS大涨超75%，将转型AI数据中心业务；NTLA涨超23%，核心产品在特定治疗领域取得重大突破>>
06-16 16:40
美股大行评级 | 大摩再上调希捷科技和西部数据目标价；多家大行首予Lincoln买入评级
今日重点评级关注：HC Wainwright & Co.：维持Elicio Therapeutics"买入"评级，目标价从17美元升至23美元；Leerink Partners：维持SAB Biotherapeutics"跑赢大市"评级，目标价从7美元升至12美元
06-16 11:34
Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder
Intellia Therapeutics, Inc. (NASDAQ:NTLA) stock is trading higher on Monday on additional positive findings from its global Phase 3 HAELO trial evaluating lonvo-z, its investigational CRISPR-based treatment for hereditary angioedema (HAE). HAE is a rare genetic disorder that causes recurrent and unp...
06-15 21:39
HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $25 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Buy and maintains $25 price target.
06-15 18:15
Intellia Therapeutics Announces That Data From The Global Phase 3 HAELO Clinical Trial Of Lonvo-Z In Hereditary Angioedema Will Be Presented At The European Academy Of Allergy & Clinical Immunology Annual Congress 2026
Intellia will also have a poster presentation detailing the burdens experienced by HAE patients living outside the United States.Late-Breaking Oral Presentation Details:Title: HAELO, a Phase 3, Global, Randomised,
06-01 19:39
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $12 Price Target
Wedbush analyst David Nierengarten reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and maintains $12 price target.
05-12 20:44
Intellia Therapeutics Q1 EPS $(0.81) Beats $(0.90) Estimate, Sales $15.048M Beat $14.793M Estimate
Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.90) by 10 percent. This is a 26.36 percent increase over losses of $(1.10) per share
05-11 19:39
